• CSPC Pharmaceutical Group announced a Phase I trial launch in China for SYH2083 dry-eye drops on October 20, 2026.
• The placebo-controlled study will evaluate safety, tolerability and pharmacokinetics following single and multiple doses in healthy participants.
• Recruitment and screening are underway; results have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261020-12376980), on October 20, 2026, and is solely responsible for the information contained therein.